Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zosurabalpin
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
Zosurabalpin is an experimental *tethered macrocyclic peptide* (MCP) antibiotic developed by Roche and scientists from Harvard University. It targets *Acinetobacter baumannii* by inhibiting the LptB2FGC complex, disrupting lipopolysaccharide (LPS) transport, which leads to the accumulation of toxic intermediates and bacterial death. It is particularly effective against carbapenem-resistant strains and has shown potent activity in both in vitro and in vivo models. Zosurabalpin is being developed for the treatment of infections caused by carbapenem-resistant *Acinetobacter baumannii* (CRAB).
- Other names
- RG6006RG-6006RG 6006Abx MCPRO7223280RO-7223280RO 7223280
02
Targets
LptC (Lipopolysaccharide export system protein LptC)
Beyond the preview
Go deeper on zosurabalpin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zosurabalpin.